Ovid Therapeutics (OVID) Competitors $0.51 +0.00 (+0.25%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.50 -0.01 (-2.05%) As of 08/7/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OVID vs. NVCT, GNLX, CGEN, KRRO, SPRO, BHST, FATE, MCRB, IMRX, and PLXShould you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Nuvectis Pharma (NVCT), Genelux (GNLX), Compugen (CGEN), Korro Bio (KRRO), Spero Therapeutics (SPRO), BioHarvest Sciences (BHST), Fate Therapeutics (FATE), Seres Therapeutics (MCRB), Immuneering (IMRX), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry. Ovid Therapeutics vs. Its Competitors Nuvectis Pharma Genelux Compugen Korro Bio Spero Therapeutics BioHarvest Sciences Fate Therapeutics Seres Therapeutics Immuneering Protalix BioTherapeutics Ovid Therapeutics (NASDAQ:OVID) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment. Which has more risk and volatility, OVID or NVCT? Ovid Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Do insiders and institutionals have more ownership in OVID or NVCT? 72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 13.1% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 30.5% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, OVID or NVCT? Nuvectis Pharma has lower revenue, but higher earnings than Ovid Therapeutics. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOvid Therapeutics$570K63.81-$26.43M-$0.35-1.46Nuvectis PharmaN/AN/A-$19M-$1.17-5.27 Does the media refer more to OVID or NVCT? In the previous week, Nuvectis Pharma had 14 more articles in the media than Ovid Therapeutics. MarketBeat recorded 14 mentions for Nuvectis Pharma and 0 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.00 beat Nuvectis Pharma's score of -0.43 indicating that Ovid Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Ovid Therapeutics Neutral Nuvectis Pharma Neutral Do analysts prefer OVID or NVCT? Ovid Therapeutics presently has a consensus price target of $3.13, indicating a potential upside of 510.95%. Nuvectis Pharma has a consensus price target of $15.33, indicating a potential upside of 148.51%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Nuvectis Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ovid Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is OVID or NVCT more profitable? Nuvectis Pharma has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -4,562.23%. Ovid Therapeutics' return on equity of -34.17% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Ovid Therapeutics-4,562.23% -34.17% -25.34% Nuvectis Pharma N/A -150.81%-94.84% SummaryOvid Therapeutics beats Nuvectis Pharma on 11 of the 16 factors compared between the two stocks. Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVID vs. The Competition Export to ExcelMetricOvid TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.28M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.18%P/E Ratio-1.4617.9729.8725.14Price / Sales63.81262.19422.9397.17Price / CashN/A41.8335.9458.58Price / Book0.537.238.105.59Net Income-$26.43M-$54.43M$3.26B$265.48M7 Day Performance2.30%0.22%0.64%1.22%1 Month Performance18.95%5.59%2.42%0.39%1 Year Performance-44.10%9.98%27.60%23.47% Ovid Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVIDOvid Therapeutics4.378 of 5 stars$0.51+0.3%$3.13+510.9%-41.5%$36.28M$570K-1.4660Upcoming EarningsNVCTNuvectis Pharma2.5055 of 5 stars$7.29+7.2%$15.33+110.3%-7.1%$142.08MN/A-6.458Earnings ReportAnalyst RevisionGNLXGenelux1.1478 of 5 stars$3.51flat$17.75+405.7%+73.1%$132.54M$10K-3.9910News CoverageEarnings ReportUpcoming EarningsCGENCompugen1.6595 of 5 stars$1.46-1.4%$4.00+174.0%-11.7%$132.07M$27.86M-9.1370Earnings ReportKRROKorro Bio1.4455 of 5 stars$15.49+11.8%$102.43+561.3%-55.4%$130.06M$2.27M-1.6470Upcoming EarningsSPROSpero Therapeutics3.8506 of 5 stars$2.26-1.7%$5.00+121.2%+76.4%$128.59M$47.98M-1.77150BHSTBioHarvest SciencesN/A$7.67-0.3%$13.67+78.2%N/A$126.28M$27.70M-15.34N/ANews CoverageUpcoming EarningsFATEFate Therapeutics3.987 of 5 stars$1.06-0.9%$3.83+261.6%-75.4%$122.63M$13.63M-0.71550Upcoming EarningsMCRBSeres Therapeutics3.1453 of 5 stars$14.78+5.6%$73.67+398.4%-13.1%$122.17M$126.32M-3.21330Earnings ReportGap UpIMRXImmuneering3.4443 of 5 stars$3.43+1.8%$13.25+286.3%+207.9%$121.27MN/A-1.7560Positive NewsPLXProtalix BioTherapeutics2.4192 of 5 stars$1.50+3.4%$15.00+900.0%+51.0%$119.41M$59.76M-11.54200 Related Companies and Tools Related Companies NVCT Alternatives GNLX Alternatives CGEN Alternatives KRRO Alternatives SPRO Alternatives BHST Alternatives FATE Alternatives MCRB Alternatives IMRX Alternatives PLX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OVID) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
